Expanding precision oncology

With precision medicine, doctors tailor treatment to the molecular features of a person’s cancer. MSK scientists have identified hundreds of cancer-related mutations, proteins, and other traits, and pioneered new targeted therapies that take aim at them.

Support precision oncology

Pinpointing molecular drivers of cancer today

Researchers in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology examine the molecular features of tumors.
MSK-IMPACT® detects 500-plus genes with cancer-related mutations and is used to match patients with targeted therapies.
MSK-ACCESS® is a liquid biopsy test used to noninvasively diagnose cancer recurrence.
MSK created the OncoKB® database to track which mutations are most clinically relevant for each kind of cancer.

To develop targeted drugs that give patients more tomorrows

The discovery of molecular drivers of cancer has revolutionized targeted therapies, which are changing and extending lives around the world, but only about one-third of patients can benefit from this science today. The MSK Campaign will help physicians and scientists to one day identify all gene changes that cause cancer and develop drugs to target each and every one.

Your generosity fuels breakthroughs that save lives

MSK patient Michael Wolff smiles while in conversation with another person.

Genetic sequencing helped MSK doctors identify a treatment that not only saved renowned jazz musician Michael Wolff’s life but opened the door to new treatment possibilities for more people with histiocytic sarcoma, a rare cancer.

MSK pediatric patient Rihanna holds the hand of an older woman and smiles.

Rihanna was born with a large sarcoma on her right arm. After testing the tumor, doctors found a genetic mutation and were able to give her the targeted therapy larotrectinib (Vitrakvi®).

MSK patients Lenny, Judah, and Michael Deutsch sit together on a marble bench with greenery behind them.

MSK-IMPACT testing revealed a hereditary cancer gene affecting (from left) Lenny, Judah, and Michael Deutsch. All three continue to be monitored.

MSK patient Giovanna Whitting leans against a fence, smiling.

Giovanna Whitting was running out of treatment options for metastatic thyroid cancer. MSK doctors matched her with a drug that takes aim at the mutation that was driving her cancer. It worked, enabling her to live a cancer-free life.

See how your gift can propel precision oncology

Translating research into cures

Through a transformative $100 million gift, longtime donors Fiona and Stanley Druckenmiller are supporting promising translational research at MSK through the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

Learn what donors can do

Accelerating progress

Donor support, including from the Tow Foundation, has fueled advances in an emerging type of precision medicine called theranostics. An MSK clinical trial led to expanded FDA approval of a targeted treatment for prostate cancer.

MSK researchers discovered that some patients are more likely than others to be matched to precision treatments based on their genetic ancestry. They’re now seeking to better understand these disparities to improve care for all.

Make a gift

Donate to MSK to fund life-changing research and care.

Donate now

Start a fundraiser

Invite your friends and family to join you in your mission.

Get started

Attend an event

Come to a fundraising event to show your support.

Browse events

To discover more ways to partner in our work, email us.

development@mskcc.org

An MSK clinician smiles as she holds a stethoscope to a patient’s chest.

The MSK Campaign: Leading Science. Changing Lives.

The MSK community is raising $6 billion by 2030 to accelerate advances across six key strategic initiatives. Learn more and join us in our mission of ending cancer for life.

Learn more about The MSK Campaign

Innovating in care delivery Pioneering discovery science Harnessing the immune system Transforming data into cures Developing the new generation of leaders